Product Description NVIGEN X™ , the Next Generation Sequencing (NGS) cancer precision profiling assay, is enabled by the state-of-the-art molecularly engineered nanoparticles, MagVigen™ and MyQuVigen™, to efficiently capture and identify molecular information from proteins, cells and nucleic acids. We are developing NVIGEN X™ into accurate, automated and FDA approved clinical instruments and reagent kits deploy-able at hundreds and thousands of hospitals, turning fatal cancers into manageable diseases. Biomarker types that can be tested include genomic DNA, RNA, cfDNA, CTC, and protein. Sample types can be blood, plasma, saliva, body fluid, and tissue.  32-gene panel, 180-gene panel and customizable gene panels are available.